Skip to main content

How long should you take Casodex for?

Medically reviewed by Melisa Puckey, BPharm. Last updated on Nov 25, 2024.

Official answer

by Drugs.com

Casodex (bicalutamide) is a medicine that you take long term. In a clinical trial the median follow up time was 160 weeks (approximately 3 years). The length of time you may be on Casodex will be depend on:

  • cancer stage
  • other cancer therapies you are using
  • how well you are responding to Casodex
  • amount and severity of side effects.

Everyone’s individual clinical picture will be different and so the length of time you are Casodex will be determined by your healthcare professional.

Casodex is an anti-androgen type of hormone therapy used to treat prostate cancer that has spread to other parts of the body.

Casodex should be taken in combination with luteinizing hormone-releasing hormone (LHRH) agonist, which is another type of hormone therapy.

References

Read next

Why has Xtandi stopped working and what do I take next?

Prostate cancer cells, like bacteria, can evolve over time and become resistant to treatments, including the hormone therapy and androgen receptor inhibitor Xtandi (enzalutamide). The cancer cells work to reprogram their environment and develop strategies that enable them to transform and survive.

If treatment with Xtandi stops working then other treatments may be offered, such as:

  • Chemotherapy
  • Immunotherapy
  • Targeted therapy
  • Radiotherapy

Stopping treatment with Xtandi may also result in an antiandrogen withdrawal response (AAWR), which can cause the cancer to stop growing or shrink for the period of time. Continue reading

How long do you take Orgovyx for?

Orgovyx (relugolix) is taken once daily for as long as it remains effective and side effects are manageable. Prostate cancer often requires long-term hormone control, and studies show Orgovyx can be used safely for up to 48 weeks. Continue reading

How long does Xtandi work?

Xtandi is typically taken until prostate cancer starts to progress or spread (metastasize), or until the patient can no longer tolerate therapy because of the side effects or adverse events it causes.

In clinical trials, Xtandi was effective at delaying the time to disease progression in men with advanced prostate cancer. In men who had not received prior treatment with chemotherapy, Xtandi was also effective at delaying the need for treatment with a cytotoxic chemotherapy agent.

In the AFFIRM trial, treatment with Xtandi extended life by almost 5 months in men with metastatic castration-resistant prostate cancer. Continue reading

Related medical questions

Drug information

Related support groups